Immune cell engagers in lung cancer

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Lung cancer treatment is advancing with immunotherapy and understanding the tumor microenvironment.
• Immune Cell Engagers (ICEs) are emerging immunotherapies that activate immune cells against tumors.
• T-cell engagers (TCEs), like bispecific T-cell engagers (BiTEs), show antitumor effects in lung cancer models.

Purpose of the Study:

• To review the mechanisms and advances of ICEs in lung cancer immunotherapy.
• To explore future directions for next-generation ICEs.
• To highlight the potential of ICEs to revolutionize lung cancer treatment.

Main Methods:

• Systematic review of recent studies on ICEs in lung cancer.
• Analysis of ICE mechanisms of action and therapeutic efficacy.
• Exploration of challenges and innovative development strategies for ICEs.

Main Results:

• TCEs enhance T-cell activity and exhibit antitumor effects in lung cancer.
• Lung cancer's heterogeneous microenvironment and immunosuppression limit ICE efficacy.
• Challenges include target specificity, non-target toxicity, and pharmacokinetics.

Conclusions:

• ICEs hold significant potential for lung cancer immunotherapy.
• Overcoming microenvironmental challenges is crucial for optimizing ICE therapy.
• Further development of ICEs may lead to paradigm shifts in lung cancer treatment.